Cannabinoids for the Treatment of Dermatologic Conditions


Torunn E. Sivesind MD, Jalal Maghfour MD, Hope Rietcheck MD, Kevin Kamel BS, Ali S. Malik MD,m Robert P.Dellavalle MD, PhD, MSPH

Published in JJID Innovations

January 2022



In recent years, cannabinoid products have gained popularity among the general public. The anti-inflammatory properties of cannabinoids have piqued the interest of researchers and clinicians, as they represent promising avenues for the treatment of autoimmune and inflammatory skin disorders that may be refractory to conventional therapy. The objective of this study was to review the existing literature regarding cannabinoids for dermatologic conditions. A primary literature search was conducted in October 2020, using the PubMed and Embase databases, for all articles published from 1965 to October 2020. Review articles, studies using animal models, non-dermatologic, and pharmacologic studies were excluded. From 248 non-duplicated studies, 26 articles were included. There were 13 articles on systemic cannabinoids and 14 reports on topical cannabinoids. Selective cannabinoid receptor type 2 (CB2) agonists were found to be effective in treating diffuse cutaneous systemic sclerosis (dcSSc) and dermatomyositis (DM). Dronabinol demonstrated efficacy for trichotillomania. Sublingual cannabidiol (CBD) and Δ-9-tetrahydrocannabinol (THC) were successful at treating pain associated with epidermolysis bullosa (EB). Available evidence suggests cannabinoids may be effective for the treatment of various inflammatory skin disorders. While promising, additional research is necessary to further evaluate efficacy, and to determine dosing, safety, and long-term treatment guidelines.

Full Paper>>

DOI: doi.org/10.1016/j.xjidi.2022.100095



Sivesind, T. E., Maghfour, J., Rietcheck, H., Kamel, K., Malik, A. S., & Dellavalle, R. P. (2022). Cannabinoids for the Treatment of Dermatologic Conditions. JID Innovations, 100095.